CHDR & Ardena Joint Webinar
Proving CNS Target Engagement in Neurodegenerative Drug Development
In neurodegenerative drug development, showing that a therapy reaches the central nervous system, engages its intended target and produces meaningful biological effects remains a major challenge. Answering it takes an integrated approach that brings together clinical pharmacology, disease-relevant models and robust bioanalysis.
date
October 19, 2026
time
11:00 AM ET
Who you'll meet
Experts from CHDR and Ardena
Is your drug reaching the right place, engaging its target and doing what it was designed to do?
Experts from CHDR and Ardena will show how their 15-year partnership helps sponsors translate complex biomarker data into actionable early-development decisions.
— What you'll learn
From biomarkers to proof-of-mechanism
- Understand how translational clinical pharmacology and bioanalysis can be aligned to move from biomarker measurement towards evidence of target engagement and clinical proof-of-mechanism.
— What you'll learn
Designing the right biomarker strategy
- Identify the key considerations when designing a context-appropriate biomarker strategy, including clinical model selection, sampling design, assay performance and the intended development decision.
— What you'll learn
Faster, data-driven decisions
- Describe how fit-for-purpose biomarker assay validation and rapid bioanalytical turnaround support data-driven decision making during early clinical development.
Webinar speakers
Using GCase and lipid biomarker case studies, the speakers will illustrate how integrated clinical and bioanalytical strategies can build a coherent chain of evidence, reduce uncertainty and strengthen confidence in proof-of-mechanism.
Speakers
How do you prove your drug is doing what it was designed to do?
Join CHDR and Ardena on October 19, 2026 at 11:00 AM ET to learn how integrated clinical and bioanalytical strategies can strengthen confidence in proof-of-mechanism.